Administrative-Core-001

项目总结（与CA 250972相同） 该计划项目赠款将建立研究和核心的完全整合的跨学科计划 这些设施是必要的，以发展一个基本的理解之间的复杂的相互作用， 在癌症治疗中迅速出现的领域：1）靶向放射性核素治疗（TRT）和2）免疫治疗。我们 总体目标是对免疫调节能力有一个详细的机制性理解， 并评价和比较这些药物引起合作治疗的能力 与免疫疗法的相互作用。为了实现这一目标，我们将采用具有代表性的各种 使用临床相关的鼠肿瘤模型和伴侣犬在体内递送辐射的TRT剂 自发性的癌症。我们将确定每种放射性核素的精确剂量， TRT载体和肿瘤模型。这将有助于研究剂量、剂量率和剂量范围依赖性 对宿主免疫系统、肿瘤浸润免疫细胞、肿瘤中细胞因子表达的影响 微环境，肿瘤细胞的免疫易感性，免疫抑制机制， 抗原特异性获得性免疫的发展。我们将确定这些功能的后果 通过测试广泛的假设，即通过调节肿瘤免疫耐受和功能性免疫耐受， 由于TRT在所有肿瘤部位都具有免疫原性，因此TRT将增加对某些癌症免疫疗法的应答。我们将测试 以下计划项目中的这一点：项目1：用于剂量测定指导的免疫调节的新型TRT， 项目2：TRT增强肿瘤细胞免疫易感性和对免疫检查点抑制剂的反应， 项目3：TRT与局部原位疫苗结合，以克服肿瘤中的免疫抑制 微环境和增强T细胞反应，项目4：TRT与肿瘤特异性疫苗，以刺激和 扩大T细胞活化。这些高度综合的项目不仅将受益于方法和研究结果 他们也将直接受益于四个重要的专业知识和服务， 核心设施：1）高级成像和剂量测定核心（AIDC），2）放射性药物和放射化学 核心（RPRC），3）生物统计学和生物信息学核心（BBC），以及4）行政核心。为补充这些 是一个强大的机构设施，将使我们能够成功地完成我们建议的研究。我们 一个多学科团队汇集了广泛的专业知识，需要调动这些资源，以追求我们的 提出的目标。这些努力将进一步受益于强有力的机构配套支持， 强大的内部咨询委员会，宝贵的行业合作，以及外部咨询的专业知识 纸板.由于我们的结果具有直接和广泛的临床转化潜力，这些研究 预示着有机会改善任何肿瘤患者的治疗，无论癌症类型，肿瘤 位置、疾病负担或患者年龄。

PROJECT SUMMARY (same as CA250972) This Program Project grant will establish the fully integrated interdisciplinary programs of research and core facilities that are necessary to develop a fundamental understanding of the complex interplay between two rapidly emerging fields in cancer therapy: 1) targeted radionuclide therapy (TRT) and 2) immunotherapy. Our overarching objectives are to develop a detailed mechanistic understanding of the immunomodulatory capacity of TRT agents and to evaluate and compare the ability of these agents to elicit cooperative therapeutic interactions in combination with immunotherapies. To achieve this, we will employ a representative variety of TRT agents to deliver radiation in vivo using clinically relevant murine tumor models and companion canines that have spontaneously developed cancers. We will determine the precise dosimetry for each radionuclide-, TRT vector-, and tumor model. This will facilitate studies of dose-, dose-rate-, and dose-range-dependent effects on the host immune system, tumor infiltrating immune cells, cytokine expression in the tumor microenvironment, immune susceptibility of tumor cells, mechanisms of immune suppression, and the development of antigenspecific adaptive immunity. We will determine the functional consequences of these effects by testing the broad hypothesis that, by modulating tumor immune tolerance and functional immunogenicity at all tumor sites, TRT will increase response to certain cancer immunotherapies. We will test this in the following Program Projects: Project 1: Novel TRTs for Dosimetry-Guided Immunomodulation, Project 2: TRT to enhance tumor cell immune susceptibility and response to immune checkpoint inhibitors, Project 3: Combining TRT with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses, Project 4: TRT with tumor-specific vaccine to stimulate and expand T-cell activation. These highly integrated projects will not only benefit from the methods and findings generated in one another, but they also will directly benefit from the expertise and service of four essential Core Facilities: 1) Advanced imaging and dosimetry core (AIDC), 2) Radiopharmaceutical and radiochemistry core (RPRC), 3) Biostatistics and bioinformatics core (BBC), and 4) Administrative core. Complementing these are robust institutional facilities that will enable successful completion of our proposed studies. Our multidisciplinary team brings together the broad expertise needed to mobilize these resources in pursuit of our proposed objectives. These efforts will further benefit from robust institutional matching support, leadership of a strong Internal Advisory Committee, invaluable Industry collaborations, and expertise of an External Advisory Board. Because of the immediate and broad potential for clinical translation of our results, these studies portend an opportunity to improve the treatment of any oncology patient, regardless of cancer type, tumor location, burden of disease, or patient age.